COMMUNIQUÉS West-GlobeNewswire

-
Radical Clean Solutions Ltd. Terminates Asset Purchase Agreement with AgriForce Growing Systems Ltd. and Files Lawsuit for Breach of Contract
30/05/2025 -
CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference
30/05/2025 -
Shareholder Update
30/05/2025 -
Syncromune® Announces First Patient Dosed in LEGION-100 Phase 2a Trial of SYNC-T® Therapy SV-102 for Patients with Metastatic Castration-Resistant Prostate Cancer
30/05/2025 -
Noom Launches Free Menopause Education Hub in Partnership with Menopause Advocate Tamsen Fadal
30/05/2025 -
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference
30/05/2025 -
Spectral AI Announces Appointment of Stanley Micek as Chief Operating Officer
30/05/2025 -
Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2025 MedTech Innovation Spotlight
30/05/2025 -
Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million
30/05/2025 -
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics
30/05/2025 -
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
30/05/2025 -
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers
30/05/2025 -
Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.
30/05/2025 -
BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages
30/05/2025 -
Conavi Medical Reports Fiscal Q2 2025 Interim Results and Operational Highlights
30/05/2025 -
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025
30/05/2025 -
Arvinas to Present at Jefferies Global Healthcare Conference
30/05/2025 -
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
30/05/2025 -
Ascend Aesthetic Partners Welcomes David Cutter as COO
30/05/2025
Pages